

# Jean-Claude Tardif

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6319841/publications.pdf>

Version: 2024-02-01

196  
papers

23,054  
citations

26567

56  
h-index

8599

146  
g-index

206  
all docs

206  
docs citations

206  
times ranked

24718  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Torcetrapib in Patients at High Risk for Coronary Events. <i>New England Journal of Medicine</i> , 2007, 357, 2109-2122.	13.9	2,811
2	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2019, 380, 11-22.	13.9	2,153
3	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015, 373, 2247-2257.	13.9	1,856
4	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2089-2099.	13.9	1,754
5	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 381, 2497-2505.	13.9	1,696
6	Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1675.	3.8	652
7	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2020, 382, 244-255.	13.9	559
8	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
9	Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes. <i>Circulation</i> , 1999, 99, 3227-3233.	1.6	497
10	Coding Variation in<i>ANGPTL4</i>,<i>LPL</i> and<i>SVEP1</i> and the Risk of Coronary Disease. <i>New England Journal of Medicine</i> , 2016, 374, 1134-1144.	13.9	427
11	Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure. <i>New England Journal of Medicine</i> , 2014, 371, 1091-1099.	13.9	399
12	The Polygenic and Monogenic Basis of Blood Traits and Diseases. <i>Cell</i> , 2020, 182, 1214-1231.e11.	13.5	388
13	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. <i>Lancet</i> , The, 2016, 388, 2142-2152.	6.3	357
14	Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. <i>Cell</i> , 2020, 182, 1198-1213.e14.	13.5	353
15	Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain. <i>Circulation</i> , 2017, 135, 2320-2332.	1.6	336
16	The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. <i>PLoS Genetics</i> , 2015, 11, e1005378.	1.5	331
17	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. <i>New England Journal of Medicine</i> , 2017, 376, 1517-1526.	13.9	307
18	Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. <i>European Heart Journal</i> , 2009, 30, 540-548.	1.0	286

#	ARTICLE	IF	CITATIONS
19	Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 304-310.	5.1	219
20	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. <i>Nature Communications</i> , 2014, 5, 5068.	5.8	216
21	Effects of Icosapent Ethyl on TotalÂIschemic Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2791-2802.	1.2	208
22	Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 2974-2982.	1.0	185
23	Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009, 158, 896-901.e3.	1.2	184
24	Pulsatile Hemodynamics in Congestive Heart Failure. <i>Hypertension</i> , 2001, 38, 1433-1439.	1.3	183
25	Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008, 371, 1761-1768.	6.3	178
26	Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2439-2445.	1.1	174
27	Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal</i> , 2020, 41, 4092-4099.	1.0	174
28	Dissociation Between Ionic Remodeling and Ability to Sustain Atrial Fibrillation During Recovery From Experimental Congestive Heart Failure. <i>Circulation</i> , 2004, 109, 412-418.	1.6	172
29	Atrial Fibrillation Promotion With Long-Term Repetitive Obstructive Sleep Apnea in a Rat Model. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2013-2023.	1.2	172
30	Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Nonâ€ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2048-2055.	1.2	164
31	Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 372-382.	5.1	158
32	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. <i>Nature Genetics</i> , 2021, 53, 128-134.	9.4	155
33	Rationale and design of <scp>REDUCEâ€T</scp>: Reduction of Cardiovascular Events with Icosapent Ethylâ€Intervention Trial. <i>Clinical Cardiology</i> , 2017, 40, 138-148.	0.7	154
34	Effects of Probucol on Vascular Remodeling After Coronary Angioplasty. <i>Circulation</i> , 1999, 99, 30-35.	1.6	134
35	Transvenous Catheter Ice Mapping and Cryoablation of the Atrioventricular Node in Dogs. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1999, 22, 1488-1498.	0.5	132
36	Canadian Cardiovascular Society Guidelines for the Diagnosis and Management of Stable Ischemic HeartÂDisease. <i>Canadian Journal of Cardiology</i> , 2014, 30, 837-849.	0.8	132

#	ARTICLE	IF	CITATIONS
37	Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 298-307.	1.3	129
38	Novel anti-inflammatory therapies for the treatment of atherosclerosis. <i>Atherosclerosis</i> , 2015, 240, 497-509.	0.4	120
39	Prevalence of Anginal Symptoms and Myocardial Ischemia and Their Effect on Clinical Outcomes in Outpatients With Stable Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2014, 174, 1651.	2.6	118
40	Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits. <i>Nature Genetics</i> , 2014, 46, 629-634.	9.4	113
41	REDUCE-IT USA. <i>Circulation</i> , 2020, 141, 367-375.	1.6	104
42	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88
43	Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. <i>Pharmacotherapy</i> , 2020, 40, 40-54.	1.2	83
44	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. <i>American Journal of Human Genetics</i> , 2016, 99, 40-55.	2.6	82
45	Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. <i>European Heart Journal</i> , 2018, 39, 4150-4158.	1.0	79
46	Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1159-1161.	1.2	79
47	Fish Oil for the Reduction of Atrial Fibrillation Recurrence, Inflammation, and Oxidative Stress. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1441-1448.	1.2	76
48	Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1769-1780.	1.2	75
49	Role of B-type Natriuretic Peptide and N-terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	75
50	A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. <i>Canadian Journal of Anaesthesia</i> , 2016, 63, 1140-1153.	0.7	73
51	Right Atrial Mechanisms of Atrial Fibrillation in a Rat Model of Right Heart Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1332-1347.	1.2	72
52	Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use. <i>Biological Psychiatry</i> , 2019, 85, 946-955.	0.7	69
53	Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Canadian Journal of Cardiology</i> , 2021, 37, 776-785.	0.8	68
54	Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation. <i>Circulation</i> , 2017, 135, 1788-1798.	1.6	66

#	ARTICLE	IF	CITATIONS
55	β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. <i>European Heart Journal</i> , 2019, 40, 1399-1407.	1.0	66
56	A Randomized Controlled, Phase 2 Trial of the Viral Serpin Serp-1 in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 543-548.	1.4	65
57	Imaging Biomarkers in Atherosclerosis Trials. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 319-333.	1.3	63
58	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	1.0	63
59	Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 340-348.	5.1	59
60	Nonsense Mutations in BAG3 are Associated With Early-Onset Dilated Cardiomyopathy in French Canadians. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1655-1661.	0.8	57
61	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. <i>European Heart Journal</i> , 2020, 41, 347-356.	1.0	55
62	High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. <i>Blood Advances</i> , 2020, 4, 2430-2438.	2.5	54
63	Prevention of Restenosis with Antioxidants. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 323-334.	1.0	52
64	Calcium Signaling Pathway Genes <i>RUNX2</i> and <i>CACNA1C</i> Are Associated With Calcific Aortic Valve Disease. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 812-822.	5.1	51
65	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. <i>American Journal of Human Genetics</i> , 2016, 99, 22-39.	2.6	50
66	Detailed characterization of microRNA changes in a canine heart failure model: Relationship to arrhythmogenic structural remodeling. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 77, 113-124.	0.9	47
67	Reduction in Revascularization With Icosapent Ethyl. <i>Circulation</i> , 2021, 143, 33-44.	1.6	46
68	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 1-26.	1.0	45
69	Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 486-495.	1.8	44
70	High-density lipoprotein/apolipoprotein A-I infusion therapy. <i>Current Atherosclerosis Reports</i> , 2009, 11, 58-63.	2.0	43
71	Heart Failure With Anemia. <i>Circulation: Heart Failure</i> , 2014, 7, 773-781.	1.6	43
72	Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension. <i>Hypertension</i> , 2018, 71, 168-176.	1.3	41

#	ARTICLE	IF	CITATIONS
73	Rationale, design, and baseline characteristics of the <scp>CLARIFY</scp> registry of outpatients with stable coronary artery disease. <i>Clinical Cardiology</i> , 2017, 40, 797-806.	0.7	40
74	Emerging high-density lipoprotein infusion therapies: Fulfilling the promise of epidemiology?. <i>Journal of Clinical Lipidology</i> , 2010, 4, 399-404.	0.6	39
75	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2021, 144, 1845-1855.	1.6	39
76	The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31798.	3.6	38
77	The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease. <i>Cardiovascular Research</i> , 2021, 117, 1776-1789.	1.8	38
78	Colchicine in Cardiovascular Disease: In-Depth Review.. <i>Circulation</i> , 2022, 145, 61-78.	1.6	37
79	Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2016, 67, 344-346.	1.2	36
80	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. <i>Circulation</i> , 2021, 144, 1750-1759.	1.6	36
81	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1660-1671.	1.2	36
82	<i>CKM</i> and <i>LILRB5</i> Are Associated With Serum Levels of Creatine Kinase. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 880-886.	5.1	35
83	Perioperative THR-184 and AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 670-679.	3.0	35
84	Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies. <i>BMC Medicine</i> , 2019, 17, 197.	2.3	35
85	Exchange protein activated by cyclic-adenosine monophosphate (Epac) regulates atrial fibroblast function and controls cardiac remodelling. <i>Cardiovascular Research</i> , 2019, 115, 94-106.	1.8	34
86	Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1362-1364.	1.2	34
87	Clinical results with AGI-1067: a novel antioxidant vascular protectant. <i>American Journal of Cardiology</i> , 2003, 91, 41-49.	0.7	32
88	Rationale, design, and methods for Canadian alliance for healthy hearts and minds cohort study (CAHHM) – a Pan Canadian cohort study. <i>BMC Public Health</i> , 2016, 16, 650.	1.2	31
89	Blood pressure and burden of hypertension in Cameroon, a microcosm of Africa. <i>Journal of Hypertension</i> , 2019, 37, 2190-2199.	0.3	31
90	Effect of Atherosclerotic Regression on Total Luminal Size of Coronary Arteries as Determined by Intravascular Ultrasound. <i>American Journal of Cardiology</i> , 2006, 98, 23-27.	0.7	28

#	ARTICLE	IF	CITATIONS
91	Coronary artery disease in 2010. <i>European Heart Journal Supplements</i> , 2010, 12, C2-C10.	0.0	28
92	ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein). <i>Circulation</i> , 2018, 138, 1677-1692.	1.6	28
93	From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants. <i>Current Opinion in Lipidology</i> , 2019, 30, 101-107.	1.2	28
94	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. <i>PLoS ONE</i> , 2020, 15, e0242318.	1.1	28
95	Cardiometabolic and traditional cardiovascular risk factors and their potential impact on macrovascular and microvascular function: Preliminary data. <i>Clinical Hemorheology and Microcirculation</i> , 2015, 59, 53-65.	0.9	27
96	CETP. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 396-400.	1.1	27
97	Apolipoprotein Aâ€ Modulates Atherosclerosis Through Lymphatic Vesselâ€Dependent Mechanisms in Mice. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	27
98	Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1069-1077.	0.8	27
99	Atrioventricular Interval Optimization and Exercise Tolerance. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 1534-1540.	0.5	26
100	Association of Atrial Fibrillation Burden With Health-Related Quality of Life After Atrial Fibrillation Ablation. <i>JAMA Cardiology</i> , 2021, 6, 1324.	3.0	26
101	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCEâ€ PCI. <i>Journal of the American Heart Association</i> , 2022, 11, e022937.	1.6	26
102	Induced KCNQ1 autoimmunity accelerates cardiac repolarization in rabbits: Potential significance in arrhythmogenesis and antiarrhythmic therapy. <i>Heart Rhythm</i> , 2014, 11, 2092-2100.	0.3	25
103	International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. <i>Circulation</i> , 2021, 144, 512-523.	1.6	25
104	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1525-1537.	1.2	25
105	The relation between hostility and concurrent levels of inflammation is sex, age, and measure dependent. <i>Journal of Psychosomatic Research</i> , 2014, 76, 384-393.	1.2	24
106	Circulating levels of linoleic acid and HDL-cholesterol are major determinants of 4-hydroxynonenal protein adducts in patients with heart failure. <i>Redox Biology</i> , 2014, 2, 148-155.	3.9	23
107	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e61-e63.	1.4	23
108	Vascular inflammation in moderateâ€toâ€severe atopic dermatitis is associated with enhanced Th2 response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3107-3121.	2.7	23

#	ARTICLE	IF	CITATIONS
109	HDL and cardiovascular risk: is cholesterol in particle subclasses relevant?. <i>European Heart Journal</i> , 2015, 36, 10-12.	1.0	22
110	Loss of Cardiomyocyte Integrin-Linked Kinase Produces an Arrhythmogenic Cardiomyopathy in Mice. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 921-932.	2.1	21
111	Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. <i>European Heart Journal</i> , 2018, 39, 3855-3863.	1.0	21
112	Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 426-436.	0.8	21
113	Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1460-1466.	0.8	21
114	Impact of hyperventilation and apnea on myocardial oxygenation in patients with obstructive sleep apnea – An oxygenation-sensitive CMR study. <i>Journal of Cardiology</i> , 2017, 69, 489-494.	0.8	18
115	Comparison of Atrial Remodeling Caused by Sustained Atrial Flutter Versus Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 374-388.	1.2	18
116	Whole-genome sequencing in French Canadians from Quebec. <i>Human Genetics</i> , 2016, 135, 1213-1221.	1.8	16
117	Role of atrial arrhythmia and ventricular response in atrial fibrillation induced atrial remodelling. <i>Cardiovascular Research</i> , 2021, 117, 462-471.	1.8	16
118	Expression of Phosphoinositide-Specific Phospholipase C Isoforms in Native Endothelial Cells. <i>PLoS ONE</i> , 2015, 10, e0123769.	1.1	16
119	Quality of Life With Ivabradine in Patients With Angina Pectoris. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 31-38.	0.9	15
120	MK5 haplodeficiency attenuates hypertrophy and preserves diastolic function during remodeling induced by chronic pressure overload in the mouse heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 313, H46-H58.	1.5	15
121	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1560-1562.	1.6	15
122	The interleukin-1 $\beta$ modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. <i>Atherosclerosis</i> , 2014, 236, 277-285.	0.4	14
123	Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 244-256.	2.3	14
124	An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation. <i>Cardiovascular Research</i> , 2019, 115, 1975-1985.	1.8	14
125	Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys. <i>Journal of Lipid Research</i> , 2017, 58, 1282-1291.	2.0	13
126	Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1795-1806.	0.8	13



#	ARTICLE	IF	CITATIONS
127	Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome. PLoS ONE, 2017, 12, e0168448.	1.1	13
128	Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. Journal of the American Heart Association, 2022, 11, e024999.	1.6	13
129	Optimisation of Reference Genes for Gene-Expression Analysis in a Rabbit Model of Left Ventricular Diastolic Dysfunction. PLoS ONE, 2014, 9, e89331.	1.1	11
130	A numerical investigation of the functionality of coronary bifurcation lesions with respect to lesion configuration and stenosis severity. Journal of Biomechanics, 2015, 48, 3103-3111.	0.9	11
131	HDL mimetic peptide CER-522 treatment regresses left ventricular diastolic dysfunction in cholesterol-fed rabbits. International Journal of Cardiology, 2016, 215, 364-371.	0.8	11
132	Resting heart rate as a predictor of aortic valve stenosis progression. International Journal of Cardiology, 2016, 204, 149-151.	0.8	11
133	Cardiovascular risk scoring and magnetic resonance imaging detected subclinical cerebrovascular disease. European Heart Journal Cardiovascular Imaging, 2020, 21, 692-700.	0.5	11
134	Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e891-e898.	1.8	11
135	Hair cortisol change at COVID-19 pandemic onset predicts burnout among health personnel. Psychoneuroendocrinology, 2022, 138, 105645.	1.3	11
136	Ivabradine and metoprolol differentially affect cardiac glucose metabolism despite similar heart rate reduction in a mouse model of dyslipidemia. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H991-H1003.	1.5	10
137	A prospective study of the impact of <i>AGTR1</i> A1166C on the effects of candesartan in patients with heart failure. Pharmacogenomics, 2018, 19, 599-612.	0.6	10
138	Cardiac inflammation and diastolic dysfunction in hypercholesterolemic rabbits. PLoS ONE, 2019, 14, e0220707.	1.1	10
139	Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2). Future Cardiology, 2021, 17, 411-414.	0.5	10
140	Effect of inhibition of the Na <sup>+</sup> /H <sup>+</sup> exchanger with cariporide on left ventricular function in acute coronary syndromes: results from the echocardiographic substudy of the GUARDIAN trial. Canadian Journal of Cardiology, 2004, 20, 317-22.	0.8	10
141	MK5 haplodeficiency decreases collagen deposition and scar size during post-myocardial infarction wound repair. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H1281-H1296.	1.5	9
142	Pillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 676-684.	0.5	8
143	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. Canadian Journal of Cardiology, 2021, 37, 1837-1845.	0.8	8
144	Pharmacogenomics to Revive Drug Development in Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2016, 30, 59-64.	1.3	7

#	ARTICLE	IF	CITATIONS
145	Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targeting and Statin Therapies. <i>Current Atherosclerosis Reports</i> , 2017, 19, 43.	2.0	7
146	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003183.	1.6	7
147	Lessons from COLCOT and LoDoCo2: colchicine for secondary prevention in coronary artery disease. <i>European Heart Journal</i> , 2021, 42, 2800-2801.	1.0	7
148	Repurposing colchicine's journey in view of drug-to-drug interactions. A review. <i>Toxicology Reports</i> , 2021, 8, 1389-1393.	1.6	6
149	Diagnosis, Prevalence, Awareness, Treatment, Prevention, and Control of Hypertension in Cameroon: Protocol for a Systematic Review and Meta-Analysis of Clinic-Based and Community-Based Studies. <i>JMIR Research Protocols</i> , 2017, 6, e102.	0.5	6
150	Aortic coarctation and the retinal microvasculature. <i>International Journal of Cardiology</i> , 2014, 174, 25-30.	0.8	5
151	Will personalized drugs for cardiovascular disease become an option? â€œ Defining â€œEvidence-based personalized medicineâ€™ for its implementation and future use. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2549-2552.	0.9	5
152	Ivabradine for the treatment of chronic heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 553-561.	0.6	5
153	Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. <i>Pharmacotherapy</i> , 2021, 41, 379-393.	1.2	5
154	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. <i>Journal of the American Heart Association</i> , 2022, 11, e021327.	1.6	5
155	Protein tyrosine phosphatase 1B regulates miR-208b-argonaute 2 association and thyroid hormone responsiveness in cardiac hypertrophy. <i>Science Signaling</i> , 2022, 15, eabn6875.	1.6	5
156	Predicting ischaemic events in the perioperative period: in search of the perfect tool. <i>Canadian Journal of Anaesthesia</i> , 1996, 43, 989-994.	0.7	4
157	Validation of patient-reported warfarin dose in a prospective incident cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 285-289.	0.9	4
158	Pharmacogenomic approaches to lipid-regulating trials. <i>Current Opinion in Lipidology</i> , 2016, 27, 557-562.	1.2	4
159	Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 81-90.	0.9	4
160	Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women. <i>Pharmacogenomics Journal</i> , 2021, 21, 446-457.	0.9	4
161	Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003219.	1.6	4
162	Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Frontiers in Pharmacology</i> , 2021, 12, 812018.	1.6	4

#	ARTICLE	IF	CITATIONS
163	The pivotal role of heart rate in clinical practice: from atherosclerosis to acute coronary syndrome. <i>European Heart Journal Supplements</i> , 2008, 10, F11-F16.	0.0	3
164	Vitamin C and Percutaneous Coronary Intervention: Some Answers, More Questions. <i>Canadian Journal of Cardiology</i> , 2014, 30, 3-5.	0.8	3
165	Acute intraoperative effect of intravenous amiodarone on right ventricular function in patients undergoing valvular surgery. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 316-325.	0.4	3
166	Investigational drugs in development for hypertriglyceridemia: a coming-of-age story. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1059-1079.	1.9	3
167	Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 287-294.	1.8	3
168	Initiation of low-dose colchicine early after myocardial infarction. <i>European Heart Journal</i> , 2021, 42, 2798-2799.	1.0	3
169	Colchicine in the Management of Acute and Chronic Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2021, 23, 120.	1.3	3
170	Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS 2 Score: Insights From the BRAIN-AF Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, , CIRCEP121010462.	2.1	3
171	Atherosclerosis imaging. <i>Canadian Journal of Cardiology</i> , 2005, 21, 1035-9.	0.8	3
172	Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1443-1453.	1.8	3
173	COMMANDER HF – A Trial and an Answer. <i>New England Journal of Medicine</i> , 2018, 379, 1372-1374.	13.9	2
174	Can ACAT inhibition limit the progression of atherosclerosis in patients with coronary artery disease?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 366-367.	3.3	1
175	A survey of the personalized medicine landscape. <i>Pharmacogenomics</i> , 2008, 9, 819-823.	0.6	1
176	Racial Disparities in Acute Coronary Syndrome Management Within a Universal Healthcare Context: Insights From the AMI-OPTIMA Trial. <i>CJC Open</i> , 2021, 3, S28-S35.	0.7	1
177	Low-Dose Colchicine for the Management of Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 867-869.	1.2	1
178	Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovanage 4). <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2008, 15, e177-87.	1.9	1
179	OUP accepted manuscript. <i>Nucleic Acids Research</i> , 2022, , .	6.5	1
180	Cardiac investigation in patients with diabetes. <i>Canadian Journal of Cardiology</i> , 2006, 22, 38A-40A.	0.8	0

#	ARTICLE	IF	CITATIONS
181	A Look Into the Future of Cardiology: Perspectives From the Montreal Heart Institute. Canadian Journal of Cardiology, 2014, 30, S399-S400.	0.8	0
182	Precision medicine to change the landscape of cardiovascular drug development. Expert Review of Precision Medicine and Drug Development, 2017, 2, 337-343.	0.4	0
183	CKing Precision in the Interpretation of Diagnostic Biomarkers. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	0
184	In Memoriamâ€”Martial G. Bourassa (1931-2020). Canadian Journal of Cardiology, 2020, 36, 1562-1563.	0.8	0
185	ApoA-I mimetic does not improve left ventricular diastolic dysfunction in rabbits without aortic valve stenosis. International Journal of Cardiology, 2021, 331, 199-205.	0.8	0
186	Mice knockdown for angiotensinâ€”like 2 spontaneously develop aortic valve stenosis. FASEB Journal, 2019, 33, 120.4.	0.2	0
187	Cardiovascular risk of chronic coronary syndrome patients according to vascular phenotype, diabetes, and smoking. European Journal of Preventive Cardiology, 2020, , .	0.8	0
188	Knockdown of ANGPTL2 promotes cardiac left ventricular dysfunction in mice via upâ€”regulation of NOX4. FASEB Journal, 2020, 34, 1-1.	0.2	0
189	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0
190	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0
191	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0
192	A genetic model of ivabradine recapitulates results from randomized clinical trials. , 2020, 15, e0236193.		0
193	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. , 2020, 15, e0242318.		0
194	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. , 2020, 15, e0242318.		0
195	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. , 2020, 15, e0242318.		0
196	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. , 2020, 15, e0242318.		0